Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BK-PIFA is an inactivated influenza A (H5N1) vaccine developed by The Research Foundation for Microbial Diseases of Osaka University (BIKEN). It is designed to provide immunity against the H5N1 avian influenza virus, which has significant pandemic potential. The vaccine is typically administered via subcutaneous injection. Clinical development in Japan has included Phase II/III trials to evaluate the safety and immunogenicity of the formulation in healthy adult volunteers. As a monovalent inactivated vaccine, it aims to induce protective antibody titers against the hemagglutinin and neuraminidase antigens of the specific H5N1 strain used in the formulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on BK-PIFA.